Myocardial no-reflow in humans

Area of Science:

• Cardiology
• Interventional Cardiology
• Myocardial Infarction Research

Background:

• No-reflow phenomenon occurs in 5-50% of ST-segment elevation myocardial infarction patients post-primary percutaneous coronary intervention.
• This condition, characterized by epicardial reperfusion without myocardial reperfusion, is linked to poorer patient prognosis.
• No-reflow has a complex pathogenesis involving distal embolization, ischemia-reperfusion injury, and microvascular predisposition.

Purpose of the Study:

• To review the multifactorial pathogenesis of no-reflow.
• To discuss current and emerging therapeutic strategies for no-reflow prevention and treatment.
• To propose a novel, personalized management approach for no-reflow based on individual patient mechanisms.

Main Methods:

• Review of existing literature on no-reflow in ST-segment elevation myocardial infarction.
• Analysis of pathogenetic components including distal embolization, ischemia-reperfusion injury, and microvascular factors.
• Evaluation of clinical parameters and biomarkers for risk stratification and mechanism assessment.

Main Results:

• Thrombus aspiration before stenting improves myocardial perfusion and outcomes compared to standard procedures by reducing distal embolization.
• Despite mechanical interventions, no-reflow can still occur, indicating varied pathogenetic relevance among patients.
• Biomarkers and clinical parameters can predict no-reflow risk and aid in understanding its underlying mechanisms.

Conclusions:

• No-reflow is a significant complication with multifactorial causes, impacting patient outcomes after myocardial infarction treatment.
• Current therapies like thrombus aspiration address some mechanisms but do not universally prevent no-reflow.
• A personalized management strategy, tailored to the predominant mechanisms in individual patients, is proposed for improved no-reflow treatment.